IDH1 and central nervous system cancer: Recent comprehensive genomic studies have identified key molecular alterations in lower-grade gliomas, including mutations in IDH1/2, TP53, ATRX, and CIC genes, along with 1p/19q codeletion in oligodendrogliomas [5,6].